

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. In the Phase I/II LIBRETTO-001 trial, seliprecatinib yielded objective responses in which of the following subsets of patients with RET-driven thyroid cancers?**
 - Only patients who had previously received cabozantinib or vandetanib
 - Only patients who had not previously received cabozantinib or vandetanib
 - Patients who had or had not previously received cabozantinib or vandetanib
- 2. Which of the following molecular aberrations is the target of the novel inhibitor entrectinib?**
 - BRAF V600E mutation
 - NTRK fusions
 - RET fusions
 - RET mutations
- 3. Which of the following adverse events is commonly associated with pralsetinib?**
 - Bone marrow suppression
 - Ocular toxicities
 - Hand-foot syndrome
- 4. Results from the pooled analysis of trials assessing larotrectinib included which of the following observations for patients with thyroid cancer and NTRK fusions?**
 - Durable responses and a tolerable safety profile
 - Short duration of responses and a tolerable safety profile
 - Short duration of responses and severe fatigue